Polynucleotide molecules containing poly(A) and their use

JP2026517592APending Publication Date: 2026-06-02SHENZHEN SHENXIN BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
SHENZHEN SHENXIN BIOTECHNOLOGY CO LTD
Filing Date
2024-03-29
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

Natural poly(A) sequences in mRNA are prone to instability and variability, leading to inconsistent mRNA stability and translation efficiency, which complicates the development and quality control of mRNA-based pharmaceutical agents.

Method used

Development of modified poly(A) polynucleotides with specific structures, including R and S elements, to enhance mRNA stability and translation efficiency, along with vectors, host cells, and lipid nanoparticles for pharmaceutical compositions.

Benefits of technology

The modified poly(A) polynucleotides improve mRNA stability and translation efficiency, enabling more controlled and effective production of pharmaceutical agents for treating diseases such as cancer, rare diseases, and infectious diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026517592000021
    Figure 2026517592000021
  • Figure 2026517592000022
    Figure 2026517592000022
  • Figure 2026517592000023
    Figure 2026517592000023
Patent Text Reader

Abstract

A polynucleotide comprising a modified poly(A) having at least 30 nucleotides. The modified poly(A) comprises: i) at least two R elements, each R element being defined as a polynucleotide consisting of A nucleotides; and ii) at least one S element. The S element is a) a nucleotide that is not an A nucleotide, or b) composed of at least two nucleotides, both of which are not A nucleotides. The total number of S elements is one less than the total number of R elements, and the S elements are connected to the R elements, and each S element is flanked at both ends by the R elements. The present invention also relates to vectors and host cells comprising polynucleotides, methods for preparing RNA using polynucleotides and RNA prepared thereby, pharmaceutical compositions or LNPs comprising polynucleotides, RNA, vectors, and / or host cells, and their uses.
Need to check novelty before this filing date? Find Prior Art